HER2 exon 20 insertion

Overview

HER2 exon 20 insertion refers to an activating alteration in the ERBB2 gene, which encodes human epidermal growth factor receptor 2 (HER2), a receptor tyrosine kinase involved in cell growth and signaling. Exon 20 insertions are a class of in-frame insertion mutations that can alter receptor conformation and promote oncogenic signaling. In clinical oncology, HER2 exon 20 insertion is most prominently discussed in non-small cell lung carcinoma (NSCLC), where it is recognized as a therapeutically relevant molecular subtype and a target for HER2-directed treatment strategies.

Biologically, HER2 is a major therapeutic target in cancer because it can drive downstream signaling pathways such as ERK-mediated proliferation and survival. Although HER2 exon 20 insertion is distinct from HER2 amplification or overexpression, it is still clinically important because it can confer sensitivity to selected HER2-targeted agents, including antibody-drug conjugates. At the same time, HER2-directed therapy can be associated with toxicity, and the mutation has been studied in the context of treatment response and adverse events.

Focus of Latest Publications

Recent publications involving HER2 exon 20 insertion have focused primarily on HER2-targeted therapy in non-small cell lung carcinoma, with trastuzumab deruxtecan (T-DXd) as the central agent. In a reported case, a 78-year-old woman with NSCLC harboring a HER2 exon 20 insertion developed grade 1 T-DXd-induced interstitial lung disease during third-line treatment. Oral corticosteroids led to radiologic improvement, and T-DXd was successfully re-administered at a reduced dose. The patient then received eight additional cycles, with tumor regression and no recurrence of ILD, highlighting the importance of early detection and management of pulmonary toxicity to preserve treatment benefit.

Across the broader set of recent HER2-focused studies, investigators also examined HER2 as a therapeutic target in other cancer contexts and in platform technologies relevant to HER2-directed care. These included a real-world analysis of HER2-positive gastroesophageal cancer treated with trastuzumab plus chemotherapy, studies of HER2-targeting antibody-drug conjugates in metastatic breast cancer, and engineering approaches using HER2-binding aptamers, nanobodies, and optogenetic antibody systems. Although these reports did not specifically study HER2 exon 20 insertion, they reinforce the expanding toolkit of HER2-directed diagnostics and therapeutics that provides the clinical backdrop for mutation-specific treatment strategies.

Additional recent work addressed HER2 biology and HER2-targeted intervention more generally, including a study showing that HER2 deficiency can cause a developmental disorder with growth retardation and craniofacial malformations, and another demonstrating that chondroitinase ABC can enhance trastuzumab activity by improving HER2 engagement in glycan-rich pancreatic cancer cells. Together with the NSCLC case report, these publications underscore the continuing clinical and translational interest in HER2 as a target, while the HER2 exon 20 insertion literature in this set remains centered on T-DXd efficacy and toxicity management.

Key Publications

• NEWJul Real-world treatment patterns, resource use, and costs in human epidermal growth factor receptor 2-negative advanced gastric/gastroesophageal junction cancer in the United States in the immune checkpoint inhibitor era. (Journal of managed care & specialty pharmacy, 2026, PMID 42341069): "Since 2021, new therapies including immune checkpoint inhibitors (ICIs) have been approved in the United States for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastroesophageal junction cancer (G/GEJC) in biomarker-selected populations."
• NEWJul The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers. (Pharmacotherapy, 2026, PMID 42324472): "Zongertinib is an irreversible tyrosine kinase inhibitor that selectively inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild-type epidermal growth factor receptor (EGFR), thereby minimizing associated toxicities."
• NEWJun Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells. (Proceedings of the National Academy of Sciences of the United States of America, 2026, PMID 42308036): "ADCs against TROP2 (Sacituzumab govitecan) or HER2 (T-DXd) have demonstrated efficacy in metastatic breast cancer, yet paradoxically, outside of HER2-amplified breast cancers, expression levels of these breast cancer-enriched epitopes in tumor biopsies have not been strongly correlated with clinical response."
• NEWJun An Aptamer-Engineered Phenotyping System for Extracellular Vesicles Based on Honeycomb-like Melamine-Formaldehyde Microspheres and Carbon Dot Nanozymes. (Analytical chemistry, 2026, PMID 42296185): "Subsequently, iron-doped carbon dot nanozymes with high peroxidase-like activity were conjugated to aptamers targeting CD63, HER2, MUC1, and PD-L1, thereby providing specific recognition and colorimetric signal amplification."
• Apr A novel algae oil-based emulsion enhances chemotherapy outcome in human cancer models. (Prostaglandins, leukotrienes, and essential fatty acids, 2026, PMID 42235481): "a HER2⁺/ER⁻ patient-derived breast cancer cell line and matched cancer-associated fibroblasts were established and characterized."
• Jun Proximity-Catalyzed In Situ Anchoring Strategy for Fluorescence-Guided Precise Delineation of Minimal Residual Disease in Breast Cancer Surgery. (Analytical chemistry, 2026, PMID 42224475): "Using breast cancer as a representative disease model and HER2 as a prototypical membrane biomarker for proof-of-concept validation, this strategy establishes a generalizable framework for tumor-specific surface labeling."
• Jun Engineering a β-Sheet Enables Bispecific Binding in Single VHH Domains. (ACS synthetic biology, 2026, PMID 42152502): "We used this platform to engineer multiple dual binders to two target combinations: EGFR/PD-L1 and HER2/TfR."
• Apr Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Gastroesophageal Cancer-A Real-World Experience. (Clinical oncology (Royal College of Radiologists (Great Britain)), 2026, PMID 42127826): "the addition of trastuzumab to chemotherapy is the standard of care for first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic gastroesophageal adenocarcinoma"
• Jun An extracellular, optogenetic antibody platform for stimulus-gated antigen recognition and modulation of cell behavior. (Cell chemical biology, 2026, PMID 42102802): "We demonstrate compatibility across diverse targets, including GFP, mCherry, and the tumor-associated antigens EGFR and HER2."
• Jun HER2 deficiency causes a developmental disorder with growth retardation and craniofacial malformations. (The Journal of clinical investigation, 2026, PMID 42060361): "Collectively, our findings define a developmental disorder that we designate GRACE syndrome (Growth Retardation and Craniofacial Malformations Caused by HER2 Deficiency), establish HER2's essential role in human growth and craniofacial morphogenesis, and reveal that HER2-targeted therapies during pregnancy can induce craniofacial defects and lifelong growth impairment in fetuses."